Researchers have demonstrated that an experimental optogenetic treatment combined with custom eyewear can restore limited visual function in patients with retinitis pigmentosa. The approach involves injecting a light-sensitive protein, ChrimsonR, into the retina, which equips retinal ganglion cells to respond to amber light. A camera integrated into specialized goggles captures real-world scenes and projects corresponding pulses of amber light onto the retina, activating the treated cells and enabling basic object detection. In a recent clinical trial, seven of ten participants showed improved light sensitivity, and four of eight who completed behavioral testing were able to locate a doorway or follow a line while wearing the goggles. The treatment did not restore the ability to read words or recognize faces. The findings, published in the New England Journal of Medicine, build on earlier work and coincide with the 2026 Nobel Prize in Physiology or Medicine awarded for optogenetics. However, the approach requires a functional optic nerve to transmit signals to the brain, limiting its applicability.
